The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
May. 15, 2018

Filed:

May. 26, 2017
Applicant:

Regulus Therapeutics Inc., San Diego, CA (US);

Inventors:

Jeremy Duffield, Seattle, WA (US);

Balkrishen Bhat, Cambridge, MA (US);

Deidre MacKenna, San Diego, CA (US);

Assignee:

Regulus Therapeutics Inc., San Diego, CA (US);

Attorney:
Primary Examiner:
Int. Cl.
CPC ...
C07H 21/02 (2006.01); C07H 21/04 (2006.01); A61K 31/70 (2006.01); C12N 15/113 (2010.01); A61K 45/06 (2006.01); A61K 31/7088 (2006.01);
U.S. Cl.
CPC ...
C12N 15/113 (2013.01); A61K 31/7088 (2013.01); A61K 45/06 (2013.01); C12N 2310/113 (2013.01); C12N 2310/313 (2013.01); C12N 2310/315 (2013.01); C12N 2310/321 (2013.01); C12N 2310/3233 (2013.01);
Abstract

Provided herein are methods for the treatment of Alport Syndrome, using modified oligonucleotides targeted to miR-21. In certain embodiments, a modified oligonucleotide targeted to miR-21 improves kidney function and/or reduces fibrosis in subjects having Alport Syndrome. In certain embodiments, administration of a modified oligonucleotide targeted to miR-21 delays the onset of end-stage renal disease in a subject having Alport Syndrome. In certain embodiments, a modified oligonucleotide targeted to miR-21 delays the need for dialysis or kidney transplant in a subject having Alport Syndrome.


Find Patent Forward Citations

Loading…